Autoinflammatory & rare systemic diseases
Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China
Authors' conclusion
Canakinumab may be effective and tolerable for Chinese CAPS patients, helping to reduce the dosage of corticosteroids.
Study context
- Population
- Chinese patients with cryopyrin-associated periodic syndrome (CAPS) treated with canakinumab40% males
- Participants
- 10 patients
- Outcome
- Treatment response by CAPS disease activity score, C-reactive protein (CRP) and/or serum amyloid A (SAA) levels
- Follow-up
- Months 1, 3, 6, 9 and 12, or last
Methodological detailssingle-group
- Single-group
Main finding
As reported in the abstract
Treatment response
Complete remission without relapse
60%
6/10
Fever and rash improved significantly
80%
Dose increase required to control disease activity
30%
3/10
Observational data: associations, not effects.
Further findings
Prednisone use
- Received prednisone before canakinumab
- 60% (6/10)
- Discontinued prednisone later
- 5
Safety
| Outcome | Values |
|---|---|
| Infection (most common AE) | Canakinumab 40% |
| Serious AEs | Canakinumab 0 events |
Original publication
Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China. Pediatr Rheumatol Online J. Published 27 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →